158 related articles for article (PubMed ID: 37031776)
1. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018.
Cook S; Pethick J; Kibbi N; Hollestein L; Lavelle K; de Vere Hunt I; Turnbull C; Rous B; Husain A; Burn J; Lüchtenborg M; Santaniello F; McRonald F; Hardy S; Linos E; Venables Z; Rajan N
J Am Acad Dermatol; 2023 Dec; 89(6):1129-1135. PubMed ID: 37031776
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinicopathologic features, survival, and demographics in sebaceous carcinoma patients with and without Muir-Torre syndrome.
Maloney NJ; Zacher NC; Hirotsu KE; Rajan N; Aasi SZ; Kibbi N
J Am Acad Dermatol; 2023 Aug; 89(2):269-273. PubMed ID: 37003478
[TBL] [Abstract][Full Text] [Related]
3. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy?
Sinson H; Karayan-Tapon L; Godet J; Rivet P; Alleyrat C; Battistella M; Pierron H; Morel F; Lecron JC; Favot L; Frouin E
Dermatology; 2023; 239(6):889-897. PubMed ID: 37717564
[TBL] [Abstract][Full Text] [Related]
5. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.
Roberts ME; Riegert-Johnson DL; Thomas BC; Thomas CS; Heckman MG; Krishna M; DiCaudo DJ; Bridges AG; Hunt KS; Rumilla KM; Cappel MA
J Genet Couns; 2013 Jun; 22(3):393-405. PubMed ID: 23212176
[TBL] [Abstract][Full Text] [Related]
6. Universal immunohistochemical screening of sebaceous neoplasms for Muir-Torre syndrome: Putting the cart before the horse?
Kim RH; Nagler AR; Meehan SA
J Am Acad Dermatol; 2016 Nov; 75(5):1078-1079. PubMed ID: 27745640
[No Abstract] [Full Text] [Related]
7. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
8. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome.
Dores GM; Curtis RE; Toro JR; Devesa SS; Fraumeni JF
Cancer; 2008 Dec; 113(12):3372-81. PubMed ID: 18932259
[TBL] [Abstract][Full Text] [Related]
9. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
[TBL] [Abstract][Full Text] [Related]
10. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
Everett JN; Raymond VM; Dandapani M; Marvin M; Kohlmann W; Chittenden A; Koeppe E; Gustafson SL; Else T; Fullen DR; Johnson TM; Syngal S; Gruber SB; Stoffel EM
JAMA Dermatol; 2014 Dec; 150(12):1315-21. PubMed ID: 25006859
[TBL] [Abstract][Full Text] [Related]
11. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
Neelakantan IV; Di Palma S; Smith CE; McCoombe A
Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
13. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
14. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.
Morales-Burgos A; Sánchez JL; Figueroa LD; De Jesús-Monge WE; Cruz-Correa MR; González-Keelan C; Nazario CM
P R Health Sci J; 2008 Dec; 27(4):322-7. PubMed ID: 19069357
[TBL] [Abstract][Full Text] [Related]
15. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
17. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
18. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
Boennelycke M; Thomsen BM; Holck S
Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous sebaceous tumours and Lynch syndrome: long-term follow-up of 60 patients.
Marcoval J; Talavera-Belmonte A; Fornons-Servent R; Bauer-Alonso A; Penín RM; Servitje O
Clin Exp Dermatol; 2019 Jul; 44(5):506-511. PubMed ID: 30430625
[TBL] [Abstract][Full Text] [Related]
20. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.
Sargen MR; Cahoon EK; Lynch CF; Tucker MA; Goldstein AM; Engels EA
JAMA Dermatol; 2020 Dec; 156(12):1307-1314. PubMed ID: 33146669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
